Tags

Type your tag names separated by a space and hit enter

Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection.
Aliment Pharmacol Ther 2000; 14(1):73-7AP

Abstract

BACKGROUND

Ranitidine bismuth citrate (RBC)-based triple therapies for a period of 7 days have proved to be an effective treatment for Helicobacter pylori.

AIM

To investigate the eradication efficacy, safety profile and patient compliance of two RBC-based triple therapies given for 5 days.

METHODS

Eighty H. pylori-positive patients with dyspeptic symptoms, referred to us for gastroscopy, were consecutively enrolled in this prospective, randomized, open-label study. These patients were randomly assigned to receive a 5-day course of RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and either tinidazole 500 mg b.d. (RBCCT group) or amoxycillin 1 g b.d. (RBCCA group). The H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13C-urea breath test 8 weeks after the completion of treatment.

RESULTS

All enrolled patients completed the study. Thirty-seven of 40 patients treated with RBCCT (both PP and ITT analysis: 93%; 95% CI: 80-98%) and 35 of 40 in the RBCCA group (both PP and ITT analysis: 88%; 95% CI: 73-96%) returned H. pylori-negative. Slight or mild side-effects occurred in 4/40 patients (10%) in the RBCCT group and in 5/40 (12%) in the RBCCA group.

CONCLUSIONS

This is the first study demonstrating the efficacy of RBC-based triple therapies given for only 5 days. RBC regimens containing high-dose clarithromycin and either amoxycillin or tinidazole prove to be well tolerated, safe and preserve good eradication rates even when administered for a shorter than conventional duration.

Authors+Show Affiliations

Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Italy. dora.erasmo@tiscalinet.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10632648

Citation

Cammarota, G, et al. "Five-day Regimens Containing Ranitidine Bismuth Citrate Plus High-dose Clarithromycin and Either Amoxycillin or Tinidazole for Helicobacter Pylori Infection." Alimentary Pharmacology & Therapeutics, vol. 14, no. 1, 2000, pp. 73-7.
Cammarota G, Cannizzaro O, Ojetti V, et al. Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14(1):73-7.
Cammarota, G., Cannizzaro, O., Ojetti, V., Cianci, R., Pastorelli, A., Armuzzi, A., ... Gasbarrini, G. (2000). Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics, 14(1), pp. 73-7.
Cammarota G, et al. Five-day Regimens Containing Ranitidine Bismuth Citrate Plus High-dose Clarithromycin and Either Amoxycillin or Tinidazole for Helicobacter Pylori Infection. Aliment Pharmacol Ther. 2000;14(1):73-7. PubMed PMID: 10632648.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. AU - Cammarota,G, AU - Cannizzaro,O, AU - Ojetti,V, AU - Cianci,R, AU - Pastorelli,A, AU - Armuzzi,A, AU - Gentiloni,N, AU - Gasbarrini,A, AU - Pirozzi,G, AU - Gasbarrini,G, PY - 2000/1/13/pubmed PY - 2000/2/19/medline PY - 2000/1/13/entrez SP - 73 EP - 7 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 14 IS - 1 N2 - BACKGROUND: Ranitidine bismuth citrate (RBC)-based triple therapies for a period of 7 days have proved to be an effective treatment for Helicobacter pylori. AIM: To investigate the eradication efficacy, safety profile and patient compliance of two RBC-based triple therapies given for 5 days. METHODS: Eighty H. pylori-positive patients with dyspeptic symptoms, referred to us for gastroscopy, were consecutively enrolled in this prospective, randomized, open-label study. These patients were randomly assigned to receive a 5-day course of RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and either tinidazole 500 mg b.d. (RBCCT group) or amoxycillin 1 g b.d. (RBCCA group). The H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13C-urea breath test 8 weeks after the completion of treatment. RESULTS: All enrolled patients completed the study. Thirty-seven of 40 patients treated with RBCCT (both PP and ITT analysis: 93%; 95% CI: 80-98%) and 35 of 40 in the RBCCA group (both PP and ITT analysis: 88%; 95% CI: 73-96%) returned H. pylori-negative. Slight or mild side-effects occurred in 4/40 patients (10%) in the RBCCT group and in 5/40 (12%) in the RBCCA group. CONCLUSIONS: This is the first study demonstrating the efficacy of RBC-based triple therapies given for only 5 days. RBC regimens containing high-dose clarithromycin and either amoxycillin or tinidazole prove to be well tolerated, safe and preserve good eradication rates even when administered for a shorter than conventional duration. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/10632648/Five_day_regimens_containing_ranitidine_bismuth_citrate_plus_high_dose_clarithromycin_and_either_amoxycillin_or_tinidazole_for_Helicobacter_pylori_infection_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2000&volume=14&issue=1&spage=73 DB - PRIME DP - Unbound Medicine ER -